2487 — Cutia Therapeutics Share News
0.000.00%
Last trade - 00:00- HK$261.16m
- -HK$151.72m
- CNY336.15m
Brief: Cutia Therapeutics Says Cu-40102 Bags Marketing Approval From Macao Pharmaceutical Administration Bureau
Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
Brief: Cutia Therapeutics Posts HY Loss Of RMB180.4 MLN
Brief: Cutia Therapeutics Says CU-30101 Obtains Drug Marketing Authorization By NMPA China
Brief: Cutia Therapeutics Says Completion Of Phase III Clinical Trial Of Cu-20101
Brief: Cutia Therapeutics Says CU-40104 Obtains Clinical Trial Approval From NMPA, China
Brief: Cutia Therapeutics Says Abbreviated New Drug Application For CU-40105 Accepted By NMPA China
Brief: Cutia Therapeutics Announces Placing Of 28.9 Million Shares
Brief: Cutia Therapeutics Says Cu-40102 Obtains Marketing Approval By Hong Kong Department Of Health
Brief: Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA
Brief: Cutia Therapeutics Posts 9M Revenue Of Group's Commercialized Products Rmb148.9 Million
Brief: Cutia Therapeutics Announces Increase In Shareholding By CEO
Brief: Cutia Therapeutics Says Increase In Shareholding By CEO And Executive Director
Brief: Cutia Therapeutics Says Increase In Shareholding By CFO And Executive Director
Brief: Cutia Therapeutics Says NMPA Accepted Drug Marketing Authorization Application For Cu-30101
Brief: Cutia Therapeutics Posts Q1 2024 Revenue Of Commercialized Products RMB34.1 Mln, Up 123.4%
Brief: Cutia Therapeutics Says Unit Obtained "Drug Manufacturing Certificate"
Brief: Cutia Therapeutics Announces Submission Of New Drug Application For CU-40102 In HK
Brief: Cutia Therapeutics Posts FY Loss Attributable RMB1.96 Billion